Prevnar®13 Eligibility

Table 1: ROUTINE Pneumococcal Conjugate Immunization

Eligible age cohort	Health status	Recommended doses of Prevnar®13	Recommended schedule
Starting at 2 months	Low risk (healthy with no medical conditions that increase the risk of IPD)	3 doses	2, 4, and 12 months of age
Starting at 2 months	High risk†	4 doses	2, 4, 6 and 15 months of age

Table 2: CATCH-UP Pneumococcal Conjugate Immunization

Eligible age cohort	Health status	History of pneumococcal conjugate vaccine	Recommended dose(s) of Prevnar®13	Recommended schedule
2 months to 59 months (<5 years)	• Low risk **or** • High risk†	• Any incomplete series with pneu-C-7 and/or pneu-C-10	1 to 3 doses depending on age at first dose	See Table 3 and Table 4 for schedules
12 months to 59 months (<5 years)	• High risk†	• Completed series with pneu-C-7 and/or pneu-C-10	1 catch-up dose	≥8 weeks after the last dose of pneumococcal conjugate vaccine
Eligible starting January 2011 2 years old or turning 2 years old in 2011	• Low risk	• Completed series with pneu-C-7 and/or pneu-C-10	1 catch-up dose	≥8 weeks after the last dose of pneumococcal conjugate vaccine

Ontario

Prevnar®13 Schedules

Table 3: Prevnar®13 schedule for **LOW RISK** children who have not completed or have not started their series

Child's current age	Vaccination history of pneumococcal conjugate vaccine	Recommended Prevnar®13 dose(s) required to complete series
2 to 6 months	0 doses	1st dose (now) 2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose and ≥12 months of age
	1 dose (1st dose)	2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose and ≥12 months of age
	2 age-appropriate doses (1st and 2nd dose)	3rd dose, ≥8 weeks after 2nd dose and ≥12 months of age
7 to 11 months	0 doses	1st dose (now) 2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose and ≥12 months of age
	1 dose (1st dose)	2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose and ≥12 months of age
	2 doses (1st and 2nd dose)	3rd dose, ≥8 weeks after 2nd dose and ≥12 months of age
12 to 23 months (<2 years)	0 doses	1st dose (now) 2nd dose, ≥8 weeks after 1st dose
	1 dose (1st dose) at <12 months of age	2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose
	1 dose (1st dose) at ≥12 months of age	2nd dose, ≥8 weeks after 1st dose
	1 dose (1st dose) at <12 months of age + 1 dose (2nd dose) at ≥12 months of age	3rd dose, ≥8 weeks after 2nd dose
	2 or more doses at <12 months of age	1 dose, ≥8 weeks after most recent dose
24 to 59 months (<5 years)	0 doses	1 dose, ≥8 weeks after most recent dose (if applicable)
	Any incomplete series	

For a list of medical conditions that increase an individual's risk for IPD, see page 3.

Prevnar®13 Schedules

Table 4: Prevnar®13 schedule for HIGH RISK† children who have not completed or have not started their series

Child's current age	Vaccination history of pneumococcal conjugate vaccine	Recommended Prevnar®13 dose(s) required to complete series
2 to 6 months	0 doses	1st dose (now) 2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose 4th dose, ≥8 weeks after 3rd dose and ≥15 months of age
	1 dose (1st dose)	2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose 4th dose, ≥8 weeks after 3rd dose and ≥15 months of age
	2 age-appropriate doses (1st and 2nd dose)	3rd dose, ≥8 weeks after 2nd dose 4th dose, ≥8 weeks after 3rd dose and ≥15 months of age
7 to 11 months	0 doses	1st dose (now) 2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose and ≥15 months of age
	1 dose (1st dose)	2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose and ≥15 months of age
	2 doses (1st and 2nd dose)	3rd dose, ≥8 weeks after 2nd dose and ≥15 months of age
12 to 23 months (<2 years)	0 doses	1st dose (now) 2nd dose, ≥8 weeks after 1st dose
	1 dose (1st dose) at <12 months of age	2nd dose, ≥8 weeks after 1st dose 3rd dose, ≥8 weeks after 2nd dose
	1 dose (1st dose) at ≥12 months of age	2nd dose, ≥8 weeks after 1st dose
	1 dose (1st dose) at <12 months of age + 1 dose (2nd dose) at ≥12 months of age	3rd dose, ≥8 weeks after 2nd dose
	2 or more doses at <12 months of age	1 dose, ≥8 weeks after most recent dose
24 to 59 months (<5 years)	0 doses	1st dose (now) 2nd dose, ≥8 weeks after 1st dose
	Any incomplete series	1 dose, ≥8 weeks after most recent dose

† Medical conditions that increase an individual's risk for IPD:

- Chronic respiratory disease (excluding asthma, except those treated with high-dose corticosteroid therapy)
- Chronic cardiac disease
- Cirrhosis
- Chronic renal disease or nephrotic syndrome
- Diabetes mellitus
- Asplenia, splenic dysfunction, sickle-cell disease and other sickle cell haemoglobinopathies
- Chronic cerebrospinal fluid leak
- Primary immune deficiency
- HIV infection and other conditions associated with immunosuppression (malignancies, long-term systemic corticosteroids and other immunosuppressive therapy)
- Solid organ transplant recipients
- Cochlear implant recipients (pre/post implant)

Note: Children 24 to 59 months of age and at high risk of IPD should also receive a dose of pneumococcal polysaccharide vaccine after the pneumococcal conjugate vaccine. Refer to the current *Publicly Funded Immunization Schedules for Ontario* at www.health.gov.on.ca/english/providers/program/immun/pdf/schedule.pdf

Catalogue No. 015492 4.4M November 2010 © Queen's Printer for Ontario 2010